Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma (ESCC) · Immunotherapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (zhenyu ding, MD) · dingzhenyu@scu.edu.cn · 18980601957

Study leads

zhenyu ding, MD
Principal Investigator
West China Hospital, Sichuan University, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Esophageal Squamous Cell Carcinoma · Immunotherapy · Biomarkers

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Borderline Resectable Carcinoma · Unresectable Cancer · Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Shantou, China

Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China